AGARWALEYE · Healthcare · Medical Instruments & Supplies
Composite scorecard: 52/100 — Quality 52 · Valuation 0 · Growth 100 · Momentum 60
| Share price | ₹484.70 |
| Market cap | ₹14,310 Cr |
| P/E ratio | 113.8 |
| P/B ratio | 7.4 |
| ROE | -54.4% |
| ROCE | 8.4% |
| Book value | ₹61.13 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,080 Cr | ₹168 Cr | 27.0% |
| 2025 | ₹1,711 Cr | ₹110 Cr | 27.0% |
| 2024 | ₹1,332 Cr | ₹95 Cr | 28.0% |
| 2023 | ₹1,018 Cr | ₹103 Cr | 27.0% |
| 2022 | ₹696 Cr | ₹43 Cr | 27.0% |
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consulta